QianJin Pharmaceutical: Subsidiary's 3 drugs are expected to be selected for national centralized procurement

Zhitong
2025.10.29 09:36

QianJin Pharmaceutical announced that its subsidiary QianJin Xiangjiang Pharmaceutical participated in the bidding for the 11th batch of national centralized drug procurement, with three products expected to be selected. The proposed winning price for Adenosylcobalamin capsules is RMB 4.88 per box, primarily supplied to Hunan, Guangxi, and Guizhou; the proposed winning price for Fluvoxamine tablets is RMB 7.14 per box, primarily supplied to Zhejiang, Fujian, and Chongqing; the proposed winning price for Dopamine hydrazine tablets is RMB 18.88 per box, primarily supplied to Sichuan, Hebei, Tianjin, and Ningxia. As of the end of the third quarter of 2025, these products have not yet generated sales in the domestic market. The company stated that the procurement period for selected products will be from the execution date of the selection results until December 31, 2028

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer